DENTSPLY SIRONA (NASDAQ:XRAY) Share Price Passes Above 200 Day Moving Average – Should You Sell?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.64 and traded as high as $11.67. DENTSPLY SIRONA shares last traded at $11.65, with a volume of 4,795,828 shares trading hands.

Analysts Set New Price Targets

A number of analysts recently weighed in on XRAY shares. Citigroup initiated coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Mizuho decreased their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barclays dropped their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Weiss Ratings cut DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Finally, UBS Group reduced their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $13.55.

DENTSPLY SIRONA Price Performance

The firm’s fifty day moving average is $10.57 and its two-hundred day moving average is $11.64. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -3.70, a P/E/G ratio of 1.39 and a beta of 0.89. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Brian T. Gladden bought 9,985 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael J. Barber bought 15,175 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average price of $9.88 per share, with a total value of $149,929.00. Following the completion of the transaction, the director directly owned 55,943 shares of the company’s stock, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 35,160 shares of company stock valued at $351,179 over the last quarter. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Southpoint Capital Advisors LP bought a new position in shares of DENTSPLY SIRONA during the 1st quarter valued at about $116,000,000. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Armistice Capital LLC lifted its stake in DENTSPLY SIRONA by 1,044.0% during the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in DENTSPLY SIRONA by 662.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after buying an additional 4,003,606 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after buying an additional 2,172,343 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.